Source comparison
BPC-157 GHK-Cu Scar Minimization: Clinical Evidence Comparison
BPC-157 VEGF upregulation, fibroblast migration, angiogenesis acceleration Days 0–14 (inflammation/proliferation) 60% faster wound closure at 500mcg/kg in rat models (Journal of Physiology and Pharmacology, 2011); 56% increased tensile strength at day 7 Subcut
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, fibroblast migration, angiogenesis acceleration
- Days 0–14 (inflammation/proliferation)
- 60% faster wound closure at 500mcg/kg in rat models (Journal of Physiology and Pharmacology, 2011); 56% increased tensile strength at day 7
- Subcutaneous or topical in DMSO
- Best for accelerating closure and granulation. Not for controlling scar quality
- GHK-Cu
- TGF-beta modulation, decorin binding, MMP regulation, collagen reorganization
- Days 15–90 (remodeling)
- 31% reduction in scar width at 1mM topical concentration (Wound Repair and Regeneration, 2015); improved collagen alignment on histology
- Topical in cream or serum base
- Best for preventing hypertrophic scar formation. Minimal impact during active inflammation
- Sequential Protocol
- Phase-targeted intervention: closure first, remodeling second
- Full wound cycle (0–90 days)
- No head-to-head RCT vs simultaneous use. Evidence is mechanistic extrapolation from separate studies
- BPC-157 subQ/topical → GHK-Cu topical
- Addresses both speed of closure and quality of matrix deposition without conflicting signals